Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
SAN RAFAEL, Calif., Jan. 28, 2016 -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 25, at 4:30 p.m. ET to discuss fourth quarter and full year 2015 financial results and provide a general business update.
Dial-in Number
U.S. / Canada Dial-in Number: (877) 303-6313
International Dial-in Number: (631) 813-4734
Conference ID: 34535772
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 34535772
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com.
Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451
